Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/42990
DC FieldValueLanguage
dc.contributor.authorDeiana, Valeriaen_US
dc.contributor.authorGómez-Cañas, Maríaen_US
dc.contributor.authorPazos, M. Ruthen_US
dc.contributor.authorFernández-Ruiz, Javieren_US
dc.contributor.authorAsproni, Battistinaen_US
dc.contributor.authorCichero, Elenaen_US
dc.contributor.authorFossa, Paolaen_US
dc.contributor.authorMuñoz, Eduardoen_US
dc.contributor.authorDeligia, Francescoen_US
dc.contributor.authorMurineddu, Gabrieleen_US
dc.contributor.authorGarcía-Arencibia, Moisésen_US
dc.contributor.authorPinna, Gerard A.en_US
dc.date.accessioned2018-11-21T11:59:19Z-
dc.date.available2018-11-21T11:59:19Z-
dc.date.issued2016en_US
dc.identifier.issn0223-5234en_US
dc.identifier.urihttp://hdl.handle.net/10553/42990-
dc.description.abstractPrevious studies have investigated the relevance and structure-activity relationships (SARs) of pyrazole derivatives in relation with cannabinoid receptors, and the series of tricyclic 1,4-dihydroindeno[1,2-c]pyrazoles emerged as potent CB2 receptor ligands. In the present study, novel 1,4-dihydroindeno[1,2-c]pyrazole and 1H-benzo[g]indazole carboxamides containing a cyclopropyl or a cyclohexyl substituent were designed and synthesized to evaluate the influence of these structural modifications towards CB1 and CB2 receptor affinities. Among these derivatives, compound 15 (6-cyclopropyl-1-(2,4-dichlorophenyl)-N-(adamantan-1-yl)-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide) showed the highest CB2 receptor affinity (Ki = 4 nM) and remarkable selectivity (KiCB1/KiCB2 = 2232), whereas a similar affinity, within the nM range, was seen for the fenchyl derivative (compound 10: Ki = 6 nM), for the bornyl analogue (compound 14: Ki = 38 nM) and, to a lesser extent, for the aminopiperidine derivative (compound 6: Ki = 69 nM). Compounds 10 and 14 were also highly selective for the CB2 receptor (KiCB1/KiCB2 > 1000), whereas compound 6 was relatively selective (KiCB1/KiCB2 = 27). The four compounds were also subjected to GTPγS binding analysis showing antagonist/inverse agonist properties (IC50 for compound 14 = 27 nM, for 15 = 51 nM, for 10 = 80 nM and for 6 = 294 nM), and this activity was confirmed for the three more active compounds in a CB2 receptor-specific in vitro bioassay consisting in the quantification of prostaglandin E2 release by LPS-stimulated BV2 cells, in the presence and absence of WIN55,212-2 and/or the investigated compounds. Modelling studies were also conducted with the four compounds, which conformed with the structural requirements stated for the binding of antagonist compounds to the human CB2 receptor.en_US
dc.languageengen_US
dc.publisher0223-5234-
dc.relation.ispartofEuropean Journal of Medicinal Chemistryen_US
dc.sourceEuropean Journal of Medicinal Chemistry [ISSN 0223-5234], v. 112, p. 66-80en_US
dc.subject32 Ciencias médicasen_US
dc.subject.otherCB(2) antagonismen_US
dc.subject.otherCannabinoid receptorsen_US
dc.subject.otherMolecular modellingen_US
dc.subject.otherSynthesisen_US
dc.subject.otherTricyclic pyrazolesen_US
dc.titleTricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB<inf>2</inf>receptor ligands with antagonist/inverse agonist propertiesen_US
dc.typeinfo:eu-repo/semantics/Articlees
dc.typeArticlees
dc.identifier.doi10.1016/j.ejmech.2016.02.005
dc.identifier.scopus2-s2.0-84981298101-
dc.identifier.isi000372558200007
dc.contributor.authorscopusid57194483512-
dc.contributor.authorscopusid47761206700-
dc.contributor.authorscopusid6701326923-
dc.contributor.authorscopusid7006533053-
dc.contributor.authorscopusid7801341853-
dc.contributor.authorscopusid23970379500-
dc.contributor.authorscopusid7004138079-
dc.contributor.authorscopusid7202348306-
dc.contributor.authorscopusid55241643800-
dc.contributor.authorscopusid6603506924-
dc.contributor.authorscopusid15821889300-
dc.contributor.authorscopusid35546140700-
dc.description.lastpage80-
dc.description.firstpage66-
dc.relation.volume112-
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngid3479936
dc.contributor.daisngid2056921
dc.contributor.daisngid1182976
dc.contributor.daisngid180726
dc.contributor.daisngid1475866
dc.contributor.daisngid749265
dc.contributor.daisngid31927177
dc.contributor.daisngid76495
dc.contributor.daisngid5628976
dc.contributor.daisngid974941
dc.contributor.daisngid1760567
dc.contributor.daisngid267952
dc.contributor.wosstandardWOS:Deiana, V
dc.contributor.wosstandardWOS:Gomez-Canas, M
dc.contributor.wosstandardWOS:Pazos, MR
dc.contributor.wosstandardWOS:Fernandez-Ruiz, J
dc.contributor.wosstandardWOS:Asproni, B
dc.contributor.wosstandardWOS:Cichero, E
dc.contributor.wosstandardWOS:Fossa, P
dc.contributor.wosstandardWOS:Munoz, E
dc.contributor.wosstandardWOS:Deligia, F
dc.contributor.wosstandardWOS:Murineddu, G
dc.contributor.wosstandardWOS:Garcia-Arencibia, M
dc.contributor.wosstandardWOS:Pinna, GA
dc.date.coverdateAbril 2016
dc.identifier.ulpgces
dc.description.sjr1,272
dc.description.jcr4,519
dc.description.sjrqQ1
dc.description.jcrqQ1
dc.description.scieSCIE
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.orcid0000-0002-1618-4487-
crisitem.author.fullNameGarcía Arencibia, Moisés-
Appears in Collections:Artículos
Show simple item record

SCOPUSTM   
Citations

21
checked on Jul 14, 2024

WEB OF SCIENCETM
Citations

20
checked on Jul 14, 2024

Page view(s)

18
checked on Jul 8, 2023

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.